Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Nvidia Develops New Location-Verification Technology for AI Chips 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Walgreens Boots Alliance Inc. (NASDAQ: WBA) is set to go private after nearly a century as a publicly traded company. Private equity firm Sycamore Partners has agreed to acquire Walgreens in a leveraged buyout worth up to $23.7 billion, including debt and potential future payouts.
Under the deal, Sycamore will pay $11.45 per share in cash, with Walgreens shareholders eligible for up to an additional $3 per share based on the sale of the company’s primary-care assets. Factoring in assumed debt, the transaction could reach a total valuation of $24 billion.
Walgreens CEO Tim Wentworth emphasized that while the company has made progress on its turnaround strategy, transitioning to a private entity will allow for more efficient restructuring. He highlighted Sycamore’s expertise in retail turnarounds as a key advantage for the company’s future growth.
The acquisition follows Walgreens' struggles in the competitive pharmacy and retail healthcare industry. By going private, Walgreens aims to streamline operations and navigate market challenges without the pressures of public trading.
The deal includes a 35-day “go-shop” period, allowing Walgreens to seek alternative offers. Pending regulatory approvals, the acquisition is expected to close in the fourth quarter of this year. Investors will closely monitor the transaction, marking one of the largest leveraged buyouts in recent years.
